Invasive Candidiasis is a major contributor to morbidity and mortality in the healthcare setting, with 5 species of Candida causing more than 90% of cases1. Fluconazole-resistant species are indistinguishable based on symptoms and gram stain alone, and require a definitive diagnosis of the causative organism to direct appropriate therapy.
Great Basin Scientific is developing a panel that simultaneously detects and differentiates the 5 most common species of Candida, in addition to the highly resistant emerging pathogen Candida auris, a highly transmissible threat in US hospitals. The panel will utilize Great Basin’s proprietary AMPED technology, a PCR-independent amplification method capable of producing results in under an hour.
Want more information?
For more information on our system or to schedule a demo, please contact Great Basin Sales.
1Pappas, P., et al. ”Clinical Practice Guidelines for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America”. CID February, 2016.